Garg S K, Chugh Y, Tripathi S K, Kumar N, Sharma P L
Department of Pharmacology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Int J Clin Pharmacol Ther Toxicol. 1993 Feb;31(2):96-9.
A comparative bioavailability study was carried out on two enteric-coated capsules (20 mg each) of omeprazole (omeprazole, Alembic: "A" and Losec, Astra, England: "B"). The in-vitro dissolution of both products "A" and "B" met the prescribed USP standard. The bioavailability of single dose (20 mg) and multiple doses (20 mg once daily for 7 days) of both products "A" and "B" were carried out in eight healthy male volunteers in a crossover design. The rate and extent of bioavailability of omeprazole was higher in product "A" following a single oral dose, suggesting its therapeutic advantage over the product "B" in the prevention of acid aspiration during surgery. In multiple dose study, the two products were found bioequivalent as assessed by AUC0-infinity, Cmax, tmax and t1/2 elimination.
对两种奥美拉唑肠溶胶囊(每粒20毫克)进行了一项生物利用度对比研究(奥美拉唑,Alembic公司的“A”和英国阿斯特拉公司的洛赛克“B”)。产品“A”和“B”的体外溶出度均符合规定的美国药典标准。采用交叉设计,在8名健康男性志愿者中对产品“A”和“B”的单剂量(20毫克)和多剂量(每日一次20毫克,共7天)的生物利用度进行了研究。单次口服给药后,产品“A”中奥美拉唑的生物利用度速率和程度更高,表明其在预防手术期间胃酸误吸方面比产品“B”具有治疗优势。在多剂量研究中,通过AUC0-无穷大、Cmax、tmax和t1/2消除评估,发现两种产品具有生物等效性。